Among immunomodulatory therapies, the blockade of PD-1/PD-L1 signaling could be a novel possible approach to reverse immunosuppression in sepsis, and upregulated expression of PD-1/PD-L1 in peripheral blood monocytes is observed in inflammatory diseases and cancers [8, 9]. Here, CD274 is linked to cancer.